Valuation: Charles River Laboratories International, Inc.

Market Cap 1.12TCr 971.5Cr 904.25Cr 830.82Cr 1.57TCr 1,06800Cr 1.6TCr 11TCr 4.19TCr 53TCr 4.21TCr 4.11TCr 1,76300Cr P/E 2026 *
37.9x
P/E 2027 * 25.4x
Enterprise Value 1.3TCr 1.13TCr 1.05TCr 965.36Cr 1.82TCr 1,24100Cr 1.85TCr 12TCr 4.86TCr 62TCr 4.89TCr 4.78TCr 2,04800Cr EV / Sales 2026 *
3.38x
EV / Sales 2027 * 3.21x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
30/07 Align Technology to add directors, launch review after deal with Elliott RE
20/07 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
13/07 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
13/07 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
13/07 Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics MT
13/07 Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches CI
13/07 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
09/07 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07/07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
02/07 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
01/07 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
18/06 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
18/06 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-10.60% - - 1.13TCr
-1.40%+3.69%-2.09%+11.41% 4.94TCr
-1.16%+13.36%+22.70%+3.92% 3.91TCr
-2.41%-0.65%+406.63%+629.40% 4.09TCr
-1.88%-3.29%+5.36%+40.37% 3.58TCr
-1.74%+8.42%+8.85%+48.87% 3.05TCr
-2.85%-3.46% - - 1.66TCr
-0.21%-4.74%+31.83%+126.49% 1.61TCr
-1.19%-3.97%-9.88%-35.13% 1.28TCr
-0.64%+3.09%+3.15%+9.37% 1.37TCr
Average -1.59%+5.78%+58.32%+104.34% 2.83TCr
Weighted average by Cap. -1.63%+6.72%+76.75%+130.46%

Financials

2026 *2027 *
Net sales 384.98Cr 333.95Cr 310.83Cr 285.59Cr 539.63Cr 37TCr 548.33Cr 3.66TCr 1.44TCr 18TCr 1.45TCr 1.41TCr 61TCr 392.14Cr 340.16Cr 316.61Cr 290.91Cr 549.66Cr 37TCr 558.53Cr 3.73TCr 1.47TCr 19TCr 1.47TCr 1.44TCr 62TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.72TCr 41Cr 271.14Cr 106.55Cr 1.35TCr 107.07Cr 104.72Cr 4.49TCr 42Cr 36Cr 34Cr 31Cr 58Cr 3.98TCr 59Cr 396.84Cr 155.95Cr 1.98TCr 156.71Cr 153.28Cr 6.57TCr
Net Debt 181.35Cr 157.32Cr 146.43Cr 134.54Cr 254.2Cr 17TCr 258.3Cr 1.72TCr 677.74Cr 8.62TCr 681.04Cr 666.09Cr 29TCr 138.52Cr 120.16Cr 111.84Cr 102.76Cr 194.16Cr 13TCr 197.29Cr 1.32TCr 517.66Cr 6.58TCr 520.18Cr 508.77Cr 22TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Trader
Investor
Global
Quality
ESG MSCI
AA